Population
Patients with congenital long QT syndrome
Design
Review
Authors
Loading...
Beta-blockers remain mainstay therapy in long QT syndrome; leaves open genotype-specific approaches pending prospective validation.
This review highlights that congenital long QT syndrome is driven by ion channel mutations, emphasizing beta-blockers as standard therapy and the future potential of genotype-specific treatments.
Xander H.T. Wehrens (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: